Skip to main content

Advertisement

Table 3 Multivariate linear regression analysis for predictors of length of treatment delay among 81,081 adult patients with pulmonary tuberculosis

From: Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age: a retrospective nationwide cohort study

   Fulfilling two specific events Fulfilling three specific events
Number Delay (day)a Coefficient P-value Delay (day)a Coefficient P-value
Age (years)
 20–34 9595 14 (1–71) Reference group   4 (0–22) Reference group  
 35–49 13,319 17 (1–77) 2.11 (0.60, 3.62) 0.006 5 (0–30) 2.61 (1.35, 3.86) <0.001
 50–64 17,347 30 (3–95) 8.13 (6.57, 9.61) <0.001 8 (0–49) 8.61 (7.38, 9.83) <0.001
 65–79 26,897 53 (8–122) 20.0 (18.6, 21.4) <0.001 20 (0–71) 17.7 (16.6, 18.9) <0.001
 80 and above 13,923 61 (12–128) 23.2 (21.6, 24.7) <0.001 30 (1–83) 22.7 (21.4, 24.0) <0.001
Sex
 Female 24,914 42 (7–110) Reference group   12 (0–56) Reference group  
 Male 56,167 35 (3–105) −6.81 (−7.68, −5.95) <0.001 11 (0–58) −2.50 (−3.21, −1.78) <0.001
Diabetes mellitus
 No 58,079 35 (4–103) Reference group   10 (0–54) Reference group  
 Yes 23,002 46 (5–118) 2.97 (2.07, 3.87) <0.001 14 (0–66) 1.39 (0.65, 2.14) <0.001
Chronic obstructive pulmonary disease
 No 74,449 33 (3–100) Reference group   10 (0–52) Reference group  
 Yes 6632 99 (32–154) 30.5 (29.1, 32.0) <0.001 49 (7–115) 23.7 (22.5, 24.9) <0.001
Malignancy
 No 74,017 33 (3–101) Reference group   9 (0–53) Reference group  
 Yes 7064 85 (32–142) 25.7 (24.3, 27.2) <0.001 44 (7–99) 19.6 (18.4, 20.7) <0.001
End-stage renal disease
 No 79,172 36 (4–105) Reference group   11 (0–56) Reference group  
 Yes 1909 92 (35–144) 26.5 (23.8, 29.1) <0.001 45 (6–108) 22.2 (20.1, 24.4) <0.001
Liver cirrhosis
 No 80,631 37 (4–107) Reference group   11 (0–57) Reference group  
 Yes 450 82 (33–138) 29.5 (24.2, 34.7) <0.001 44 (7–99) 24.1 (19.8, 28.5) <0.001
Autoimmune disease
 No 80,262 37 (4–107) Reference group   11 (0–57) Reference group  
 Yes 819 63 (13–133) 14.2 (10.3, 18.1) <0.001 23 (0–80) 9.59 (6.35, 12.8) <0.001
Acquired immunodeficiency syndrome
 No 80,632 37 (4–107) Reference group   11 (0–57) Reference group  
 Yes 449 61 (7–132) 27.9 (22.6, 33.2) <0.001 19 (0–76) 20.7 (16.4, 25.1) <0.001
Organ transplantation
 No 80,957 37 (4–107) Reference group     
 Yes 124 83 (42–145) 15.4 (5.34, 25.5) 0.003    
Pneumoconiosis
 No 81,015 37 (4–107) Reference group   11 (0–57) Reference group  
 Yes 66 109 (63–158) 35.9 (22.2, 49.6) <0.001 64 (14–118) 27.2 (16.0, 38.4) <0.001
Low income
 No 78,213 37 (4–106) Reference group   11 (0–57) Reference group  
 Yes 2868 51 (5–126) 10.1 (7.94, 12.2) <0.001 14 (0–74) 7.88 (6.13, 9.64) <0.001
Location of the initial healthcare visits
 Rural area 21,437 36 (4–103) Reference group   10 (0–52) Reference group  
 Urban area 59,644 38 (4–109) 3.36 (2.46, 4.26) <0.001 12 (0–60) 4.32 (3.58, 5.07) <0.001
MTB-NAAT
 No 72,998 38 (4–107) Reference group   11 (0–58) Reference group  
 Yes 8083 35 (5–104) −2.20 (−3.51, −0.90) 0.001 13 (0–55) −1.04 (−2.11, 0.04) 0.058
  1. Abbreviation: AIDS acquired immunodeficiency syndrome, COPD chronic obstructive pulmonary disease, MTB–NAAT Mycobacterium tuberculosis–nucleic acid amplification test
  2. aData are expressed as the median (1st–3rd quartiles)